4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:主营:ELISA、抗体、试剂、试剂盒、细胞培养、转染、MHC四聚体、蛋白质和肽、四聚体和单体等
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > Specialty_ELISA_kits > MBL(CycLex&CircuLex)/CircuLex人PCSK9 ELISA试剂盒/CY-8079/96分析
商品详细MBL(CycLex&CircuLex)/CircuLex人PCSK9 ELISA试剂盒/CY-8079/96分析
MBL(CycLex&CircuLex)/CircuLex人PCSK9 ELISA试剂盒/CY-8079/96分析
MBL(CycLex&CircuLex)/CircuLex人PCSK9 ELISA试剂盒/CY-8079/96分析
商品编号: CY-8079
品牌: CycLex & CircuLex
市场价: ¥9083.15
美元价: 6987.04
产地: 美国(厂家直采)
公司:
产品分类: 特色ELISA试剂盒
公司分类: Specialty_ELISA_kits
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍
ComponentsMicroplate,WashBuffer,DilutionBuffer,PCSK9Standard,HRPconjugatedDetectionAntibody,SubstrateReagent,StopSolution
IntendeduseThisKitisusedforthequantitativemeasurementofHumanPCSK9inserum,plasma,cellculturemediumandotherBIOLOGicalmedia.
Storagetemp.4°CManufacturerMBL
Animalspecies
[GeneID]
Human
SampleSerum,Plasma,Cellculturemedium,Otherbiologicalmedia
Measurementrange0.16~10ng/mL
Sensitivity0.154ng/mL~
Citations
  1. NoguchiTetal.TheE32KvariantofPCSK9exacerbatesthephenotypeoffamilialhypercholesterolaemiabyincreasingPCSK9functionandconcentrationinthecirculation.Atherosclerosis210,166-172(2010)(PMID:20006333)
  1. CariouBetal.AssociationbetweenplasmaPCSK9andgamma-glutamyltransferaselevelsindiabeticpatients.Atherosclerosis211,700-702(2010)(PMID:20452593)
  1. CostetPetal.PlasmaPCSK9isincreasedbyFenofibrateandAtorvastatininanonadditivefashionindiabeticpatients.Atherosclerosis212,246-251(2010)(PMID:20619837)
  1. NoguchiTetal.Comparisonofeffectsofbezafibrateandfenofibrateoncirculatingproproteinconvertasesubtilisin/kexintype9andADIpocytokinelevelsindyslipidemicsubjectswithimpairedglucosetoleranceortype2diabetesmellitus:Resultsfromacrossoverstudy.Atherosclerosis217,165-70(2011)(PMID:21411093)
  1. MayneJetal.NovelLoss-of-FunctionPCSK9VariantIsAssociatedwithLowPlasmaLDLCholesterolinaFrench-CanadianFamilyandwithImpairedProcessingandSecretioninCellCulture.ClinChem.57,1415(2011)(PMID:21813713)
  1. VergèsBetal.LackofassociationbetweenplasmaPCSK9andLDL-apoB100catabolisminpatientswithuncontrolledtype2diabetes.Atherosclerosis.219,342-8(2011)(PMID:21889145)
  1. LenaPersson.StudiesonPCSK9intheregulationofcholesterolmetabolism.PublishedbyKarolinskaInstitutet.Stockholm2011
  1. CariouBetal.ClinicalaspectsofPCSK9.Atherosclerosis.216,258-65(2011)(PMID:21596380)
  1. PerssonLetal.EndogenousEstrogensLowerPlasmaPCSK9andLDLCholesterolButNotLp(a)orBileAcidSynthesisinWomen.ArteriosclerThrombVascBiol.32,810-4(2011)(PMID:22207727)
  1. KawashiriMAetal.EfficacyandSafetyofCoadmiNISTrationofRosuvastatin,Ezetimibe,andColestimideinHeterozygousFamilialHypercholesterolemia.AmJCardiol.109,364-9(2011)(PMID:22112743)
  1. LindholmMWetal.PCSK9LNAAntisenseOligonucleotidesInduceSustainedReductionofLDLCholesterolinNonhumanPrimates.MolTher.20,376-81(2012)(PMID:22108858)
  1. CameronJetal.Serumlevelsofproproteinconvertasesubtilisin/kexintype9insubjectswithfamilialhypercholesterolemiaindicatethatproproteinconvertasesubtilisin/kexintype9isclearedfromplasmabylow-densitylipoproteinreceptor_independentpathways.TranslationalResearch.160,125-30(2012)(PMID:22683370)
  1. HuijgenRetal.PlasmalevelsofproproteinconvertasesubtilisinKexintype9(PCSK9)andphenotypicvariABIlityinfamilialhypercholesterolemia.JLipidRes.53,979-83(2012)(PMID:22375030)
  1. CariouBetal.PlasmaPCSK9concentrationsduringanoralfatloadandaftershorttermhigh-fat,high-fathigh-proteinandhigh-fructosediets.NutrMetab.10,4(2013)(PMID:23298392)
  1. LeeCJetal.Associationofserumproproteinconvertasesubtilisin/kexintype9withcarotidintimamediathicknessinhypertensivesubjects.Metabolism.62,845-50(2013)(PMID:23380568)
  1. LeBrasMetal.PlasmaPCSK9isalatebioMarkerofseverityinpatientswithseveretraumainjury.JClinEndocrinolMetab.98,E732-6(2013)(PMID:23450051)
  1. MayneJetal.DifferentialeffectsofPCSK9lossoffunctionvariantsonserumlipidandPCSK9levelsinCaucasianandAfricanCanadianpopulations.LipidsHealthDis.12,70(2013)(PMID:23663650)
  1. PeticcaPetal.HumanSerumPCSK9IsElevatedatParturitioninComparisontoNonpregnantSubjectsWhileSerumPCSK9fromUmbilicalCordBloodisLowerComparedtoMaternalBlood.ISRNEndocrinol.2013,341632(2013)(PMID:23862071)
  1. TremblayAJetal.Short-term,high-fatdietincreasestheexpressionofkeyintestinalgenesinvolvedinlipoproteinmetabolisminhealthymen.AmJClinNutr.98,32-41(2013)(PMID:23719552)
  1. ConwayVetal.Impactofbuttermilkconsumptiononplasmalipidsandsurrogatemarkersofcholesterolhomeostasisinmenandwomen.NutrMetabCardiovascDis.23,1255-62(2013)(PMID:23786821)
  1. LambertGetal.ElevatedplasmaPCSK9levelisequallydetrimentalforpatientswithnonfamilialhypercholesterolemiaandheterozygousfamilialhypercholesterolemia,irrespectiveoflow-densitylipoproteinreceptordefects.JAmCollCardiol.63,2365-73(2014)(PMID:24632287)
  1. WernerCetal.Riskpredictionwithproproteinconvertasesubtilisin/kexintype9(PCSK9)inpatientswithstablecoronarydiseaseonstatintreatment.VasculPharmacol.62,94-102(2014)(PMID:24685817)
  1. AbujradHetal.ChronickidneydiseaseonhemodialysisisassociatedwithdecreasedserumPCSK9levels.Atherosclerosis.233,123-9(2014)(PMID:24529132)
  1. JiaYJetal.Short-andlong-termeffectsofXuezhikang(),anextractofcholestin,onserumproproteinconvertasesubtilisin/kexintype9levels.ChinJIntegrMed.(2014)(PMID:24993334)
  1. BondeYetal.ThyroidhormonereducesPCSK9andstimulatesbileacidsynthesisinhumans.JLipidRes.55,2408-15(2014)(PMID:25172631)
  1. MbikayMetal.Quercetin-3-glucosideincreaseslow-densitylipoproteinreceptor(LDLR)expression,attenuatesproproteinconvertasesubtilisin/kexin9(PCSK9)secretion,andstimulatesLDLuptakebyHuh7humanhepatocytesinculture.FEBSOpenBio.4,755-62(2014)(PMID:25349780)
  1. IggmanDetal.Roleofdietaryfatsinmodulatingcardiometabolicriskduringmoderateweightgain:arandomizeddouble-blindoverfeedingtrial(LIPOGAINstudy).JAmHeartAssoc.3,e001095(2014)(PMID:25319187)
  1. XuRXetal.RelationofplasmaPCSK9levelstolipoproteinsubfractionsinpatientswithstablecoronaryarterydisease.LipidsHealthDis.13,188(2014)(PMID:25496400)
  1. GhoshMetal.InfluenceofphysiologicalchangesinendogenousestrogenoncirculatingPCSK9andLDLcholesterol.JLipidRes.56,463-9(2015)(PMID:25535288)
  1. XuRXetal.ImpactsofezetimibeonPCSK9inrats:studyontheexpressionindifferentorgansandthepotentialmechanisms.JTranslMed.13,87(2015)(PMID:25889684)
  1. StarrAEetal.β-Estradiolresultsinaproproteinconvertasesubtilisin/kexintype9-dependentincreaseinlow-densitylipoproteinreceptorlevelsinhumanhepaticHuH7cells.FEBSJ.282,2682-96(2015)(PMID:25913303)
  1. RosqvistFetal.Potentialroleofmilkfatglobulemembraneinmodulatingplasmalipoproteins,geneexpression,andcholesterolmetabolisminhumans:arandomizedstudy.AmJClinNutr.102,20-30(2015)(PMID:26016870)
  1. ButkinareeCetal.AmyloidPrecursor-likeProtein2andSortilinDoNotRegulatethePCSK9Convertase-mediatedLowDensityLipoproteinReceptorDegradationbutInteractwithEachOther.JBiolChem.290,18609-20(2015)(PMID:26085104)
  1. vanPelgeestEPetal.Antisense-mediatedreductionofproproteinconvertasesubtilisin/kexintype9(PCSK9):afirst-in-humanrandomized,placebo-controlledtrial.BrJClinPharmacol.80,1350-61(2015)(PMID:26261033)
  1. WassefHetal.TheapoB-to-PCSK9ratio:Anewindexformetabolicriskinhumans.JClinLipidol.9,664-75(2015)(PMID:26350813)
  1. Si-TayebKetal.Urine-sample-derivedhumaninducedpluripotentstemcellsasamodeltostudyPCSK9-mediatedautosomaldominanthypercholesterolemia.DisModelMech.9,81-90(2016)(PMID:26586530)
  1. RogacevKSetal.PCSK9PlasmaConcentrationsAreIndependentofGFRandDoNotPredictCardiovascularEventsinPatientswithDecreasedGFR.PLoSOne11,e0146920(2016)(PMID:26799206)
  1. MiasanAetal.EffectsofLDLReceptorModulationonLymphaticFunction.SciRep.6,27862(2016)(PMID:27279328)
  1. VlachopopulosCetal.Predictionofcardiovasculareventswithlevelsofproproteinconvertasesubtilisin/kexintype9:Asystematicreviewandmeta-analysis.Atherosclerosis.252,50-60(2016)(PMID:27501130)
  1. LiSetal.Novelcirculatinglipidmeasurementsforcurrentdyslipidemiasinnon-treatedpatientsundergoingcoronaryangiography:PCSK9,apoC3andsdLDL-C.Oncotarget8,12333-12341(2017)(PMID:27713142)
  1. NavareseEPetal.AssociationofPCSK9withplateletreactivityinpatientswithacutecoronarysyndrometreatedwithprasugrelorticagrelor:ThePCSK9-REACTstudy.IntJCardiol.227,644-649(2017)(PMID:27810295)
  1. SuzukiYetal.BiodegradablelipidnanoparticlesinduceaprolongedRNAinterference-mediatedproteinknockdownandshowrapidhepaticclearanceinmiceandnonhumanprimates.IntJPharm.519,34-43(2017)(PMID:28089936)
  1. LiSetal.Novelandtraditionallipid-relatedbiomarkersandtheircombinationsinpredictingcoronaryseverity.SciRep.7,360(2017)(PMID:28336922)
  1. HyrinaAetal.Treatment-InducedViralCureofHepatitisCVirus-InfectedPatientsInvolvesaDynamicInterplayamongthreeImportantMolecularPlayersinLipidHomeostasis:CirculatingmicroRNA(miR)-24,miR-223,andProproteinConvertaseSubtilisin/KexinType9.EBioMedicine.23,68-78(2017)(PMID:28864162)
  1. BlanchardCetal.Roux-en-Ygastricbypassreducesplasmacholesterolindiet-inducedobesemicebyaffectingtrans-intestinalcholesterolexcretionandintestinalcholesterolabsorption.IntJObes.(2017)Inpress.(PMID:29135972)
Productcategory
Researcharea
Metabolism
Drugdiscovery
品牌介绍
MBL酪氨酸激酶测定试剂盒酪氨酸激酶分为两个主要家族:受体酪氨酸激酶(RTK)和细胞质蛋白(非受体酪氨酸激酶)。受体酪氨酸激酶(RTK)是许多生长因子,细胞因子和激素的高亲和力细胞表面受体。这两个家族在多种细胞信号转导途径中起着至关重要的作用,调节着细胞分裂,粘附,血管生成和存活等多种过程。这些在许多类型的癌症的发生和发展中也起主要作用。CycLex c-Src激酶测定/抑制剂筛选试剂盒旨在测量c-Src重组催化结构域的活性,用于快速,灵敏地评估抑制剂或活化剂。非受体蛋白酪氨酸激酶的Src家族在各种细胞信号转导途径中起着至关重要的作用,调节细胞分裂,运动,粘附,血管生成和存活等各种过程。Src家族激酶的组成型激活变体,包括病毒癌蛋白v-Src和v-Yes,能够诱导多种细胞类型的恶性转化。Src家族激酶,最值得注意的是,尽管并非唯一,但在多种上皮癌和非上皮癌中经常过度表达和/或异常激活。